CRON
XNAS
Market cap1.11bUSD
Nov 20, Last price
3.04USD
1D
-1.30%
1Q
-8.16%
Jan 2017
175.66%
IPO
1,742.42%
Name
Cronos Group Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Cronos Group Inc. functions as a diversified global cannabinoid enterprise. Within the United States, it manufactures, promotes, and distributes a variety of hemp-derived supplements and cosmetic products. These items are available under its Lord Jones and Happy Dance brands through online sales, traditional retail, and hospitality partner networks. The company also plays a significant role in the cultivation, production, and commercialization of cannabis and cannabis-infused products for both medicinal and adult-use sectors. Its comprehensive product offerings encompass dried cannabis flower, pre-rolled joints, edibles, concentrated forms, and cannabis extracts. These are distributed via wholesale partnerships and direct-to-consumer channels, prominently featuring its wellness platform, PEACE NATURALS, and its adult-use brand, Spinach. Moreover, Cronos Group exports dried cannabis and cannabis oils to international markets including Germany, Israel, and Australia. Established in 2012, the company maintains its corporate headquarters in Toronto, Canada.
Key people
Michael Gorenstein
Executive Chairman of the Board, President, Chief Executive Officer · since 2022
Anna Shlimak
Chief Financial Officer, Senior Vice President · since 2025
Shannon Buggy
Senior Vice President, Global Head of People · since 2020
Adam Wagner
Senior Vice President, Head of Cronos Israel · since 2024
Arye Weigensberg
Senior Vice President, Head of Research & Development · since 2022
Ran Gorelik
General Manager, Cronos Israel
Jeffrey Jacobson
Chief Growth Officer · since 2022
Terry Doucet
General Counsel and Corporate Secretary · since 2022
James Rudyk
Lead Independent Director · since 2018
Jason Adler
Independent Director · since 2016
Kendrick Ashton
Independent Director · since 2021
Murray Garnick
Independent Director · since 2019
Kamran Khan
Independent Director · since 2023
Dominik Meier
Independent Director · since 2023
Elizabeth Seegar
Independent Director · since 2023
Headquarters & legal address
111 Peter Street, Unit 300
Toronto, ON M5V 2H1
CA
Toronto, ON M5V 2H1
CA
Previous name
PHARMACAN CAPITAL CORP.
Previous name
SEARCHTECH VENTURES INC.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||